JP2011507888A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011507888A5 JP2011507888A5 JP2010539814A JP2010539814A JP2011507888A5 JP 2011507888 A5 JP2011507888 A5 JP 2011507888A5 JP 2010539814 A JP2010539814 A JP 2010539814A JP 2010539814 A JP2010539814 A JP 2010539814A JP 2011507888 A5 JP2011507888 A5 JP 2011507888A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- imidazo
- phenylamino
- pyridine
- amide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 19
- 239000003814 drug Substances 0.000 claims 11
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 241000124008 Mammalia Species 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 230000002159 abnormal effect Effects 0.000 claims 5
- 230000010261 cell growth Effects 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 125000001475 halogen functional group Chemical group 0.000 claims 5
- 230000003463 hyperproliferative Effects 0.000 claims 5
- 230000002401 inhibitory effect Effects 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 200000000018 inflammatory disease Diseases 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- BTCSRBXVTIUKLJ-UHFFFAOYSA-N 8-(4-bromo-2-chloroanilino)-N-(2-hydroxyethoxy)imidazo[1,5-a]pyridine-7-carboxamide Chemical compound OCCONC(=O)C=1C=CN2C=NC=C2C=1NC1=CC=C(Br)C=C1Cl BTCSRBXVTIUKLJ-UHFFFAOYSA-N 0.000 claims 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 2
- 229940121363 anti-inflammatory agents Drugs 0.000 claims 2
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims 1
- GERXWWPNRKXYSR-UHFFFAOYSA-N 8-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)imidazo[1,5-a]pyridine-7-carboxamide Chemical compound OCCONC(=O)C=1C=CN2C=NC=C2C=1NC1=CC=C(I)C=C1F GERXWWPNRKXYSR-UHFFFAOYSA-N 0.000 claims 1
- JKDBQRTZRZJBKK-UHFFFAOYSA-N 8-(2-fluoro-4-methylsulfanylanilino)-N-(2-hydroxyethoxy)imidazo[1,5-a]pyridine-7-carboxamide Chemical compound FC1=CC(SC)=CC=C1NC1=C(C(=O)NOCCO)C=CN2C1=CN=C2 JKDBQRTZRZJBKK-UHFFFAOYSA-N 0.000 claims 1
- GSNDENNNEIFRCS-UHFFFAOYSA-N 8-(4-bromo-2-fluoroanilino)-N-(2-hydroxyethoxy)imidazo[1,5-a]pyridine-7-carboxamide Chemical compound OCCONC(=O)C=1C=CN2C=NC=C2C=1NC1=CC=C(Br)C=C1F GSNDENNNEIFRCS-UHFFFAOYSA-N 0.000 claims 1
- HKUKICKULNJTHG-JTQLQIEISA-N 8-(4-bromo-2-fluoroanilino)-N-[(2S)-2-hydroxypropoxy]imidazo[1,5-a]pyridine-7-carboxamide Chemical compound C[C@H](O)CONC(=O)C=1C=CN2C=NC=C2C=1NC1=CC=C(Br)C=C1F HKUKICKULNJTHG-JTQLQIEISA-N 0.000 claims 1
- WFNLHIXTARCTSK-UHFFFAOYSA-N 8-(4-cyclopropyl-2-fluoroanilino)-N-(1-hydroxy-2-methylpropan-2-yl)oxyimidazo[1,5-a]pyridine-7-carboxamide Chemical compound OCC(C)(C)ONC(=O)C=1C=CN2C=NC=C2C=1NC(C(=C1)F)=CC=C1C1CC1 WFNLHIXTARCTSK-UHFFFAOYSA-N 0.000 claims 1
- SXXAGUWDTVENNX-UHFFFAOYSA-N 8-(4-cyclopropyl-2-fluoroanilino)-N-(2-hydroxyethoxy)imidazo[1,5-a]pyridine-7-carboxamide Chemical compound OCCONC(=O)C=1C=CN2C=NC=C2C=1NC(C(=C1)F)=CC=C1C1CC1 SXXAGUWDTVENNX-UHFFFAOYSA-N 0.000 claims 1
- RUULLUPEQNPHPE-LBPRGKRZSA-N 8-(4-cyclopropyl-2-fluoroanilino)-N-[(2S)-2-hydroxypropoxy]imidazo[1,5-a]pyridine-7-carboxamide Chemical compound C[C@H](O)CONC(=O)C=1C=CN2C=NC=C2C=1NC(C(=C1)F)=CC=C1C1CC1 RUULLUPEQNPHPE-LBPRGKRZSA-N 0.000 claims 1
- JYPIRWXVRCGARK-UHFFFAOYSA-N 8-(4-cyclopropyl-2-fluoroanilino)imidazo[1,5-a]pyridine-7-carboxamide Chemical compound NC(=O)C=1C=CN2C=NC=C2C=1NC(C(=C1)F)=CC=C1C1CC1 JYPIRWXVRCGARK-UHFFFAOYSA-N 0.000 claims 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive Effects 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- -1 cyclic amine Chemical class 0.000 claims 1
- 125000004990 dihydroxyalkyl group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
Claims (30)
- 式I:
[上式中、
Z1はCR1であり;
R1はH、C1−C3アルキル、ハロ、CF3、CHF2、CN、ORA又はNRARAであり;
R1’はH、C1−C3アルキル、ハロ、CF3、CHF2、CN、ORA、又はNRARAであり;
ここで、それぞれのRAは独立してH又はC1−C3アルキルであり;
Z2はCR2であり;
Z3はCR3はであり;
R2及びR3は独立してH、ハロ、CN、CF3、又はC1-C12アルキルであり;
R4はH、C1-C6アルキルであり;
YはW-C(O)-であり;
Wは
であり;
R5はH又はC1-C12アルキルであり;
X1は-OR11'であり;
R11'はC1-C12アルキル、C1-C12ヒドロキシアルキル、C1-C12ジヒドロキシアルキル又はRa又はRbが独立して水素又はC1−3アルキルであるか、又はRaとRbはそれらが結合している窒素と一緒になって、5又は6員環の環状アミンを形成する(CH2)nNRaRbであり;
X4は
であり;
R6はハロ、C1-C6アルキル、C2-C8アルキニル、C3−4シクロアルキル又はC1ー12アルキルチオであり;
R6'はH、ハロ又はC1-C6アルキルであり;
pは0、1又は2である]
の化合物及びその塩。 - R2がH、メチル、CF3、Cl、又はFである、請求項1の化合物。
- R2がH、Cl又はFである、請求項2の化合物。
- R3がH、メチル、CF3、Cl、又はFである、請求項2の化合物。
- R3がH、Cl又はFである、請求項4の化合物。
- R1がH又はメチルである、請求項4の化合物。
- R1がHである、請求項8の化合物。
- R1’がHである、請求項7の化合物。
- R4がH又はメチルである、請求項11の化合物。
- R4がHである、請求項12の化合物。
- R5がH又はメチルである、請求項12の化合物。
- R5がHである、請求項14の化合物。
- 8−(4−シクロプロピル−2−フルオロ−フェニルアミノ)−イミダゾ[1,5−a]ピリジン−7−カルボン酸アミド;
8−(4−シクロプロピル−2−フルオロ−フェニルアミノ)−イミダゾ[1,5−a]ピリジン−7−カルボン酸(2−ヒドロキシ−エトキシ)−アミド;
8−(2−フルオロ−4−メチルスルファニル−フェニルアミノ)−イミダゾ[1,5−a]ピリジン−7−カルボン酸(2−ヒドロキシ−エトキシ)−アミド;
8−(2−フルオロ−4−ヨード−フェニルアミノ)−イミダゾ[1,5−a]ピリジン−7−カルボン酸(2−ヒドロキシ−エトキシ)−アミド;
8−(4−シクロプロピル−2−フルオロ−フェニルアミノ)−イミダゾ[1,5−a]ピリジン−7−カルボン酸((S)−2−ヒドロキシ−プロポキシ)−アミド;
8−(4−シクロプロピル−2−フルオロ−フェニルアミノ)−イミダゾ[1,5−a]ピリジン−7−カルボン酸(2−ヒドロキシ−1,1−ジメチル−エトキシ)−アミド;
8−(4−ブロモ−2−フルオロ−フェニルアミノ)−イミダゾ[1,5−a]ピリジン−7−カルボン酸(2−ヒドロキシ−エトキシ)−アミド;
8−(4−ブロモ−2−フルオロ−フェニルアミノ)−イミダゾ[1,5−a]ピリジン−7−カルボン酸((S)−2−ヒドロキシ−プロポキシ)−アミド;
8−(4−ブロモ−2−クロロ−フェニルアミノ)−イミダゾ[1,5−a]ピリジン−7−カルボン酸(2−ヒドロキシ−エトキシ)−アミド; 及び、
8−(4−ブロモ−2−クロロ−フェニルアミノ)−イミダゾ[1,5−a]ピリジン−7−カルボン酸(2−ヒドロキシ−エトキシ)−アミド
から選択される化合物である請求項1の化合物。 - 請求項1、3から5及び6から16の何れか一項の化合物、及び薬学的に許容可能な担体を含む、薬学的組成物。
- 付加的な化学療法剤を更に含む、請求項17の薬学的組成物。
- 付加的な抗炎症剤を更に含む、請求項17の薬学的組成物。
- 治療的な有効量の請求項17の薬学的組成物を含む、ほ乳類において異常細胞増殖を阻害する又は過剰増殖性障害を治療するための医薬。
- 治療的な有効量の請求項17の薬学的組成物を含む、ほ乳類において炎症性疾患を治療するための医薬。
- 治療的な有効量の請求項18の薬学的組成物を含む、ほ乳類において異常細胞増殖を阻害する又は過剰増殖性障害を治療するための医薬。
- 治療的な有効量の、請求項19の薬学的組成物を含む、ほ乳類における炎症疾患の治療のための医薬。
- 付加的な化学療法剤を更に含む、請求項20の医薬。
- 付加的な抗炎症剤を更に含む、請求項21の医薬。
- ほ乳類において異常細胞増殖を阻害する又は過剰増殖性障害を治療するための医薬の製造における請求項1から16の何れかの化合物の使用。
- ほ乳類において炎症性疾患を治療するための医薬の製造における請求項1から16の何れかの化合物の使用。
- ほ乳類において異常細胞増殖を阻害する又は過剰増殖性障害を治療するための医薬の製造における請求項18の何れかの薬学的組成物の使用。
- ほ乳類において炎症性疾患を治療するための医薬の製造における請求項19の何れかの薬学的組成物の使用。
- ほ乳類において異常細胞増殖を阻害する又は過剰増殖性障害を治療するための医薬の製造における、更に第二の化学的療法剤を含んでなる請求項24の薬学的組成物の使用。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1515507P | 2007-12-19 | 2007-12-19 | |
US61/015,155 | 2007-12-19 | ||
US5402408P | 2008-05-16 | 2008-05-16 | |
US61/054,024 | 2008-05-16 | ||
PCT/US2008/087476 WO2009085980A1 (en) | 2007-12-19 | 2008-12-18 | 8-anilin0imidaz0pyridines and their use as anti-cancer and/or anti-inflammatory agents |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2011507888A JP2011507888A (ja) | 2011-03-10 |
JP2011507888A5 true JP2011507888A5 (ja) | 2012-02-23 |
JP5710268B2 JP5710268B2 (ja) | 2015-04-30 |
Family
ID=40404998
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010539814A Expired - Fee Related JP5710268B2 (ja) | 2007-12-19 | 2008-12-18 | 8−アニリノイミダゾピリジン及びその抗ガン及び/又は抗炎症剤としての使用 |
Country Status (16)
Country | Link |
---|---|
US (1) | US8293763B2 (ja) |
EP (1) | EP2231662B1 (ja) |
JP (1) | JP5710268B2 (ja) |
KR (1) | KR20100101666A (ja) |
CN (1) | CN101903387B (ja) |
AT (1) | ATE513832T1 (ja) |
AU (1) | AU2008343062B2 (ja) |
CA (1) | CA2704125A1 (ja) |
DK (1) | DK2231662T3 (ja) |
IL (1) | IL205490A (ja) |
NZ (1) | NZ585306A (ja) |
PL (1) | PL2231662T3 (ja) |
PT (1) | PT2231662E (ja) |
RU (1) | RU2498985C2 (ja) |
WO (1) | WO2009085980A1 (ja) |
ZA (1) | ZA201003046B (ja) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2008343065B2 (en) * | 2007-12-19 | 2012-04-05 | Genentech, Inc. | 5-anilinoimidazopyridines and methods of use |
AU2010276537B2 (en) | 2009-07-27 | 2015-04-16 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
MX2012015096A (es) | 2010-07-02 | 2013-05-28 | Gilead Sciences Inc | Compuestos heterociclicos fusionados como moduladores del canal ion. |
EP2707361B1 (en) | 2011-05-10 | 2017-08-23 | Gilead Sciences, Inc. | Fused heterocyclic compounds as sodium channel modulators |
NO3175985T3 (ja) | 2011-07-01 | 2018-04-28 | ||
TWI622583B (zh) | 2011-07-01 | 2018-05-01 | 基利科學股份有限公司 | 作為離子通道調節劑之稠合雜環化合物 |
EP2755483B1 (en) | 2011-09-14 | 2018-11-28 | Samumed, LLC | Indazole-3-carboxamides and their use as wnt/b-catenin signaling pathway inhibitors |
PH12017500997A1 (en) | 2012-04-04 | 2018-02-19 | Samumed Llc | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
KR101223245B1 (ko) * | 2012-09-12 | 2013-01-17 | 삼부기술 주식회사 | 영상이미지의 기준점 대비 도화하기 위한 대상 지형지물을 촬영하는 공간 영상도화 시스템 |
US9532987B2 (en) | 2013-09-05 | 2017-01-03 | Genentech, Inc. | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases |
CA2927541C (en) | 2013-10-15 | 2021-06-08 | Radux Devices, LLC | Securing a medical device to a valve instrument |
TWI720451B (zh) | 2014-02-13 | 2021-03-01 | 美商英塞特控股公司 | 作為lsd1抑制劑之環丙胺 |
WO2015123437A1 (en) | 2014-02-13 | 2015-08-20 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
US9670210B2 (en) | 2014-02-13 | 2017-06-06 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
EP3392244A1 (en) | 2014-02-13 | 2018-10-24 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
WO2016007736A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyrazines as lsd1 inhibitors |
US9758523B2 (en) | 2014-07-10 | 2017-09-12 | Incyte Corporation | Triazolopyridines and triazolopyrazines as LSD1 inhibitors |
US9695167B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors |
TWI687419B (zh) | 2014-07-10 | 2020-03-11 | 美商英塞特公司 | 作為lsd1抑制劑之咪唑并吡啶及咪唑并吡嗪 |
CN108358939A (zh) * | 2014-07-29 | 2018-08-03 | 上海科州药物研发有限公司 | 作为蛋白激酶抑制剂的杂环化合物及其制备方法和用途 |
WO2016040193A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof |
WO2016040185A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof |
WO2016040180A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
WO2016040181A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
WO2016040184A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
EA201792205A1 (ru) | 2015-04-03 | 2018-02-28 | Инсайт Корпорейшн | Гетероциклические соединения как ингибиторы lsd1 |
GB201511790D0 (en) | 2015-07-06 | 2015-08-19 | Iomet Pharma Ltd | Pharmaceutical compound |
US10206909B2 (en) | 2015-08-03 | 2019-02-19 | Samumed, Llc | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
WO2017024021A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof |
US10519169B2 (en) | 2015-08-03 | 2019-12-31 | Samumed, Llc | 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
WO2017024015A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
US10463651B2 (en) | 2015-08-03 | 2019-11-05 | Samumed, Llc | 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-indazoles and therapeutic uses thereof |
US10231956B2 (en) | 2015-08-03 | 2019-03-19 | Samumed, Llc | 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
WO2017023987A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof |
WO2017023975A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof |
US10604512B2 (en) | 2015-08-03 | 2020-03-31 | Samumed, Llc | 3-(1H-indol-2-yl)-1H-indazoles and therapeutic uses thereof |
US10206908B2 (en) | 2015-08-03 | 2019-02-19 | Samumed, Llc | 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof |
US10285983B2 (en) | 2015-08-03 | 2019-05-14 | Samumed, Llc | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof |
WO2017023993A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-indol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
WO2017023989A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
WO2017023980A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof |
WO2017023972A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
AU2016306555B2 (en) | 2015-08-12 | 2021-01-28 | Incyte Holdings Corporation | Salts of an LSD1 inhibitor |
WO2017079759A1 (en) | 2015-11-06 | 2017-05-11 | Samumed, Llc | 2-(1h-indazol-3-yl)-3h-imidazo[4,5-c]pyridines and their anti-inflammatory uses thereof |
KR20180134347A (ko) | 2016-04-15 | 2018-12-18 | 제넨테크, 인크. | 암의 진단 및 치료 방법 |
US10166221B2 (en) | 2016-04-22 | 2019-01-01 | Incyte Corporation | Formulations of an LSD1 inhibitor |
MX2018014871A (es) | 2016-06-01 | 2019-11-05 | Samumed Llc | Proceso de preparacion de n-(5-(3-(7-(3-fluorofenil)-3h-imidazo[4, 5-c]piridin-2-il)-1h-indazol-5-il)piridin-3-il)-3-metilbutanamida . |
EP3528808B1 (en) | 2016-10-21 | 2021-10-06 | BioSplice Therapeutics, Inc. | Methods of using indazole-3-carboxamides and their use as wnt/b-catenin signaling pathway inhibitors |
JP2019533702A (ja) | 2016-11-07 | 2019-11-21 | サミュメッド リミテッド ライアビリティ カンパニー | 単回用量の調整済み注射用製剤 |
EP3679159A1 (en) | 2017-09-08 | 2020-07-15 | H. Hoffnabb-La Roche Ag | Diagnostic and therapeutic methods for cancer |
US20210008047A1 (en) | 2018-02-13 | 2021-01-14 | Vib Vzw | Targeting minimal residual disease in cancer with rxr antagonists |
WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
WO2024033381A1 (en) | 2022-08-10 | 2024-02-15 | Vib Vzw | Inhibition of tcf4/itf2 in the treatment of cancer |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU6068600A (en) | 1999-07-16 | 2001-02-05 | Warner-Lambert Company | Method for treating chronic pain using mek inhibitors |
HU230251B1 (hu) | 2000-07-19 | 2015-11-30 | Warner-Lambert Co. | 4-Jód-fenil-amino-benzhidroxámsav-észter-származékok és ezeket tartalmazó gyógyászati készítmények |
PL214231B1 (pl) * | 2001-04-27 | 2013-07-31 | Eisai R & D Man Co | Pochodne pirazolo [1,5-a] pirydyny, kompozycje je zawierajace oraz zastosowanie |
PL401637A1 (pl) | 2002-03-13 | 2013-05-27 | Array Biopharma Inc. | N3 alkilowane pochodne benzimidazolu jako inhibitory MEK |
PA8569201A1 (es) | 2002-03-13 | 2004-05-21 | Array Biopharma Inc | "derivados de bencimidazol n3 alquilado como inhibidores de mek" "n3 alkylated benzimimidazole derivatives as mek inhibitors" |
JP3764440B2 (ja) * | 2002-05-24 | 2006-04-05 | 日東電工株式会社 | 光学フィルムの製造方法 |
GB0226724D0 (en) * | 2002-11-15 | 2002-12-24 | Merck Sharp & Dohme | Therapeutic agents |
SE0301373D0 (sv) * | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Novel compounds |
US7144907B2 (en) * | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
US7538120B2 (en) * | 2003-09-03 | 2009-05-26 | Array Biopharma Inc. | Method of treating inflammatory diseases |
WO2005051302A2 (en) * | 2003-11-19 | 2005-06-09 | Array Biopharma Inc. | Bicyclic inhibitors of mek and methods of use thereof |
MY145634A (en) * | 2003-12-29 | 2012-03-15 | Bristol Myers Squibb Co | Pyrrolotriazine compounds as kinase inhibitors |
AU2005311451A1 (en) * | 2004-12-01 | 2006-06-08 | Merck Serono Sa | [1,2,4]triazolo[4,3-a]pyridine derivatives for the treatment of hyperproliferative diseases |
-
2008
- 2008-12-18 NZ NZ585306A patent/NZ585306A/en not_active IP Right Cessation
- 2008-12-18 DK DK08868471.7T patent/DK2231662T3/da active
- 2008-12-18 EP EP08868471A patent/EP2231662B1/en active Active
- 2008-12-18 RU RU2010129910/04A patent/RU2498985C2/ru not_active IP Right Cessation
- 2008-12-18 AT AT08868471T patent/ATE513832T1/de active
- 2008-12-18 US US12/808,346 patent/US8293763B2/en not_active Expired - Fee Related
- 2008-12-18 WO PCT/US2008/087476 patent/WO2009085980A1/en active Application Filing
- 2008-12-18 AU AU2008343062A patent/AU2008343062B2/en not_active Ceased
- 2008-12-18 CN CN200880122184.1A patent/CN101903387B/zh not_active Expired - Fee Related
- 2008-12-18 KR KR1020107015816A patent/KR20100101666A/ko active IP Right Grant
- 2008-12-18 JP JP2010539814A patent/JP5710268B2/ja not_active Expired - Fee Related
- 2008-12-18 PT PT08868471T patent/PT2231662E/pt unknown
- 2008-12-18 PL PL08868471T patent/PL2231662T3/pl unknown
- 2008-12-18 CA CA2704125A patent/CA2704125A1/en not_active Abandoned
-
2010
- 2010-04-30 ZA ZA2010/03046A patent/ZA201003046B/en unknown
- 2010-05-02 IL IL205490A patent/IL205490A/en not_active IP Right Cessation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2011507888A5 (ja) | ||
JP2011526926A5 (ja) | ||
JP2009507909A5 (ja) | ||
JP2015511638A5 (ja) | ||
JP2011526924A5 (ja) | ||
JP2011529073A5 (ja) | ||
JP2007505877A5 (ja) | ||
JP2013010792A5 (ja) | ||
JP2005519932A5 (ja) | ||
JP2008195730A5 (ja) | ||
JP2016506387A5 (ja) | ||
RU2008142841A (ru) | СОЕДИНЕНИЯ ИМИДАЗО-[1, 2-b]-ПИРИДАЗИНА (ВАРИАНТЫ), СПОСОБ ПОЛУЧЕНИЯ СОЕДИНЕНИЙ ИМИДАЗО-[1, 2-b]-ПИРИДАЗИНА (ВАРИАНТЫ), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И ЛЕКАРСТВЕННОЕ СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ И/ИЛИ ПРЕДУПРЕЖДЕНИЯ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С МОДУЛЯЦИЕЙ ГАМКА РЕЦЕПТОРОВ | |
JP2005511531A5 (ja) | ||
JP2008509187A5 (ja) | ||
JP2010509356A5 (ja) | ||
JP2012041365A5 (ja) | ||
JP2013512903A5 (ja) | ||
JP2005528443A5 (ja) | ||
JP2007522162A5 (ja) | ||
JP2009526831A5 (ja) | ||
ATE402707T1 (de) | Imidazoä1,5aütriazoloä1,5dübenzodiazepin- derivative zur behandlung kognitiver störungen | |
JP2009513604A5 (ja) | ||
JP2007515476A5 (ja) | ||
JP2011507896A5 (ja) | ||
TWI455938B (zh) | 碳酸啶衍生物及其醫藥組成物 |